News

Under the first phase of the contract, Human Genome Sciences will receive $1.8 million to supply ten grams of ABthrax to the US Department of Health and Human

The technology, known as UCOE (ubiquitous chromatin opening element), improves the yield, consistency and stability of protein production in cultured mammalian cells, allowing simpler and quicker generation of

LigoCyte’s intranasal anthrax vaccine is a dual-antigen vaccine that protects against both the anthrax toxin and the infectious disease process. The dry powder formulation offers the potential for

VivaGel has already been successfully tested in a number of studies including a phase I human safety trial. This new funding will accelerate the progress of VivaGel to

In a mouse model of human prostate cancer, PSMA ADC (prostate-specific membrane antigen antibody-drug conjugate) significantly prolonged overall survival up to nine-fold as compared to untreated animals. Remarkably,

The product is recombinant human Mannan-Binding Lectin (rhMBL), a protein therapeutic being developed for the prevention of severe infections in MBL-deficient individuals undergoing chemotherapy. Enzon receives exclusive worldwide

Nektar’s novel drug-device system uses a nebulizer and Nektar proprietary adapter technology, along with a unique formulation of liquid antibiotics, to target the lungs directly with preventative doses

If the collaboration is successful it could lead to treatments that reduce the frequency of injections required to treat blood clotting disorders such as hemophilia A. Lipoxen will

In conjunction with a request from the FDA, Lilly submitted to regulatory agencies an analysis of adverse event data from its Strattera clinical trials database that identified a